Enzyme combination promotes acute myelogenous leukemia progression

03/12/2014 | Oncology Nurse Advisor online

The combination of the SYK enzyme and a mutated form of the FLT3 enzyme promotes the progression of acute myelogenous leukemia, according to a study in the journal Cancer Cell. Researchers found that patients with the genetic mutation FLT3-ITD, which causes overproduction of the FLT3 enzyme, were at higher risk for AML progression and are difficult to treat. Animal studies suggest that the drug quizartinib and an SYK blocker may be useful in treating patients with the FLT3 alteration.

View Full Article in:

Oncology Nurse Advisor online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT